Sarepta shares halve after FDA digs in heels, Wedbush downgrades
Sarepta Therapeutics shares halve as FDA strong arms on opposing muscle drug and broker Wedbush downgrades the stock in light of the regulatory wrestle
Company
Sarepta Therapeutics Inc
NASDAQ:SRPT
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases.
45 stories · page 3 of 3
Trending - How low can oil go?
Capital Economics gives a typical economists' answer: on the one hand, $20 a barrel look feasible, while on the other, $50 a barrel looks likely by the end of the decade.
Sarepta plunges as FDA may reject its drug candidate eteplirsen
The FDA says in a report that effects patients may have seen while on the drug are “too small and variable.”
U.S. stock-index futures little changed ahead of Fed minutes; Etsy tumbles
U.S. stock-index futures were little changed ahead of closely watched Federal Reserve minutes that could give clues to the timing of a first interest-rate hike. Futures for the Dow Jones Industrial Average rose 22 points to 18,305, indicati